Clinical trial · Interventional
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Adenocarcinoma | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Carcinoma | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Lynch Syndrome | — | UNRESOLVED | — |
| Relatives | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic Counseling | Other | — | UNRESOLVED |
| Genetic Testing | Other | — | UNRESOLVED |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
| Mutation Carrier Screening | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Comprehensive LS genetic testing
- description
- Testing for inherited forms of cancer and tumor sequencing
- interventionNames
- Other: Genetic Counseling
- Other: Genetic Testing
- Other: Laboratory Biomarker Analysis
- Procedure: Mutation Carrier Screening
Primary outcomes (2)
- measure
- Incidence of endometrial cancer patients with Lynch syndrome
- timeFrame
- Up to 3 years
- description
- Measured by molecular profiling of tumor deoxyribonucleic acid (DNA) via next-generation sequencing.
- measure
- Incidence of tumors with microsatellite instability and/or somatic POLE mutations
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult women who had a hysterectomy or diagnostic biopsy proving endometrial adenocarcinoma (any stage) between 10/1/2017 and 4/30/2020, and received care at one of the participating hospitals * Adult relatives of the EC patients found to have LS Exclusion Criteria: * Individuals must be able to speak and read English; non-English speaking individuals will be excluded * Individuals must be able to consent for themselves; those who are unable to consent for themselves for any reason will be excluded * Prisoners will be specifically excluded from participation in the study * Women who have uterine sarcomas are excluded * Pregnant women are not eligible for the study
References
Publications (0)
Data not yet available